Background: The appearance of solid tumors und lymphomas during treatment with fingolimod was observed in studies and has been described in case reports.
Objective: To report a case of primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis (MS) with fingolimod.
Methods: Case study.
Results: Our patient developed a lymphoma a few weeks after initialization of therapy with fingolimod; 5 weeks after discontinuation of treatment the lesions resolved.
Conclusion: Causality of fingolimod is indicated by the fact that the skin lesions appeared after commencement of treatment and resolved after discontinuation of therapy. This case serves as a reminder of the potential side effects of fingolimod.
Keywords: Fingolimod; adverse side effects; lymphoma; multiple sclerosis; primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma; skin.
© The Author(s), 2016.